Eledon Pharmaceuticals (ELDN) Stock News

Eledon (Nasdaq: ELDN) announced that Steven Perrin, Ph.D., President and Chief Scientific Officer, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 10:00 a.m. ET (7:00 a.m. PT).

According to the company, the session will be webcast live with a replay available afterward on Eledon’s website under Events.

Eledon Pharmaceuticals (Nasdaq: ELDN) will present 24-month follow-up data from eight patients in a Phase 1b long-term extension evaluating tegoprubart in de novo kidney transplant recipients at the American Society of Transplant Surgeons Winter Symposium, January 23–25, 2026.

Key results from the eight-patient cohort: no biopsy-proven acute rejection, no graft loss, no deaths, no new-onset diabetes mellitus, and no de novo donor-specific antibody formation during the study period. Mean eGFR rose from 67.0 mL/min/1.73 m² at 12 months to 74.2 mL/min/1.73 m² at 24 months. Poster #62 will be presented January 23, 2026; the poster will be posted in the company's Investors section after the presentation.

Eledon Pharmaceuticals (Nasdaq: ELDN) summarized 2025 progress and provided a 2026 outlook centered on tegoprubart development across kidney allotransplantation, islet transplantation and xenotransplantation. Key 2025 results: Phase 2 BESTOW showed a mean eGFR of 69 mL/min/1.73 m² (n=51) at 12 months and demonstrated non-inferiority versus tacrolimus on an efficacy-failure composite (22.2% vs. 17.2% using a 20% non-inferiority margin). Investigator-led islet transplants (UChicago) reported insulin independence in the first six patients. Tegoprubart was used in four pig-to-human xenotransplants (three at MGH). The company completed a $57.5 million financing, expected to fund operations into 2Q 2027. Anticipated 2026 milestones include FDA guidance on Phase 3 design and multiple long-term data readouts.

Eledon Pharmaceuticals (Nasdaq: ELDN) announced that CEO David-Alexandre C. Gros, M.D. will participate in a fireside chat at the 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT).

The session will be available via live webcast with a replay accessible on the company website under Events for registered attendees.

Eledon (NASDAQ: ELDN) reported preliminary results from the first six type 1 diabetes patients in an investigator-initiated islet transplant trial using tegoprubart as the core tacrolimus-free immunosuppressant.

All six subjects achieved and maintained insulin independence after one or two transplants; three patients have been insulin-free >15 months, one reached HbA1c 4.7% for >15 months, two patients reached insulin independence ≈4 weeks post-transplant with HbA1c <6% for >3 months, and a sixth is insulin-free with HbA1c 5.3%. No serious infections, thromboembolic events, rejection events, or kidney/neurologic toxicities were reported.

Eledon Pharmaceuticals (Nasdaq: ELDN) reported Q3 2025 results and business highlights on Nov 14, 2025. Key points: Phase 2 BESTOW data showed tegoprubart with a favorable safety profile and an eGFR of approximately 69 mL/min/1.73m2 at 12 months in the treatment arm (n=51), supporting plans to advance to Phase 3 after regulator discussions. The company completed an underwritten public offering on Nov 13, 2025, raising $57.5 million gross (net ≈ $53.6M) to fund transplantation programs. Cash and short-term investments were $93.4 million as of Sept 30, 2025. Anticipated 2026 milestones include FDA guidance and initiation of a Phase 3 kidney transplant trial.

Eledon Pharmaceuticals (NASDAQ: ELDN) priced an underwritten public offering on Nov 12, 2025 to raise approximately $50 million gross. The offering includes 15,152,485 shares of common stock at $1.65 per share and, in lieu of common stock to certain investors, 15,151,515 pre-funded warrants at $1.649 each; the pre-funded warrants are immediately exercisable at $0.001 per share. Eledon granted underwriters a 30-day option to purchase up to 4,545,600 additional shares. The offering is expected to close on or about Nov 13, 2025, with net proceeds intended to support clinical development and general corporate purposes.

Eledon Pharmaceuticals (NASDAQ: ELDN) announced an underwritten public offering of shares of common stock and, for certain investors, pre-funded warrants to purchase common stock.

The company will grant underwriters a 30-day option to buy up to 15% additional shares (overallotment). The offering is subject to market and other conditions and may not be completed. Leerink Partners and Cantor are joint book-running managers.

Eledon intends to use net proceeds to support continued clinical development of product candidates, advance pipeline programs, and for general corporate purposes. The offering is made under a Form S-3 registration (File No. 333-282260) declared effective October 2, 2024, with a preliminary prospectus supplement to be filed with the SEC.

Eledon (NASDAQ: ELDN) reported Phase 2 BESTOW results for tegoprubart in kidney transplantation presented at ASN Kidney Week on November 6, 2025.

In a 127-patient randomized trial (tegoprubart n=63, tacrolimus n=64) tegoprubart produced a 12-month mean eGFR ≈69 mL/min/1.73 m² vs 66 mL/min/1.73 m² for tacrolimus, showed non-inferiority on the FDA composite efficacy-failure endpoint (22% vs 17% using a 20% margin), and demonstrated substantially lower rates of new-onset diabetes, tremor, delayed graft function and some cardiovascular events. Cash was ~$93.4M at 9/30/2025, funding operations into late 2026.